Epitalon vs Sermorelin: Different Goals, Different Evidence

Key takeaways

• They are sold side by side for sleep and aging but do different things. Sermorelin makes your pituitary release its own growth hormone; epitalon is claimed to switch on telomerase and restore melatonin rhythms.
• Sermorelin has an FDA approval history (Geref, for children with growth hormone deficiency) and small human trials in older adults showing higher growth hormone and, at adequate doses, IGF-1. Epitalon's evidence is cell culture, mice and a few small human reports measuring markers.
• Neither has been shown to slow aging or improve sleep in a controlled trial.
• Sermorelin's side effects are known and mostly minor; epitalon's are unknown, with a theoretical cancer concern FDA's reviewers raised.
• Only sermorelin is legal to compound in October 2026, at about $150 to $400 a month through telehealth. Epitalon has no legal US product.

The direct answer: epitalon and sermorelin are not two versions of the same thing. Sermorelin is a fragment of a human hormone with an FDA approval history, small trials in older adults and a legal prescription path; it raises your own growth hormone. Epitalon is a synthetic four-amino-acid peptide with a telomere theory, mouse lifespan data and almost no human evidence, and no US pharmacy may make it in 2026. If you must choose, the evidence and the law both point to sermorelin, and only for a documented reason. Our epitalon profile has the full evidence review, and our epitalon dosage guide sets its studied doses against what sellers list.

Side by side

Different goals

Sermorelin works on the growth hormone axis. Injected under the skin, usually at bedtime, it signals the pituitary to release a pulse of its own growth hormone, which drives the liver to make IGF-1. It is the shortest fragment of GHRH that keeps the hormone's full activity (Prakash & Goa 1999). Because the body's feedback stays intact, it nudges the axis rather than overriding it, and it needs a working pituitary.

Epitalon is sold on two other ideas. The first is telomeres: its developers reported that, in a dish, it switched on telomerase in human fetal lung fibroblasts and lengthened their telomeres (FDA epitalon review 2026). The second is melatonin: in small studies it raised evening melatonin in old monkeys (FDA epitalon review 2026) and a urinary melatonin marker in women with low output (Ivko 2020). Neither idea has been tied to a health outcome in people.

So the two are bought for overlapping reasons (sleep, recovery, aging) but act on unrelated systems. They are not substitutes, and comparing them is really comparing two levels of evidence.

Different evidence

Sermorelin's trials are small, old and real. In 10 healthy men with a mean age of 68, sermorelin at 1 mg twice daily for 14 days restored 24-hour growth hormone and IGF-1 to the levels of men in their twenties, while 0.5 mg twice daily did not reach significance; fasting glucose did not change (Corpas 1992). In 11 men aged 64 to 76 with low IGF-1, 2 mg nightly for 6 weeks raised overnight growth hormone but not IGF-1; 2 of 6 strength measures improved, and body composition did not change (Vittone 1997). In 10 women and 9 men aged 55 to 71, a modified GHRH analog given nightly for 16 weeks after a single-blind placebo period raised growth hormone and IGF-1 and increased lean mass in men only; sleep quality was unaffected (Khorram 1997). In children with growth hormone deficiency, 30 mcg/kg at bedtime increased growth over 12 months, the use for which sermorelin was approved (Prakash & Goa 1999).

Epitalon's evidence is one level down at every step. The telomere work is cell culture. The lifespan work is mice: in 54 female mice injected 5 days a month for life, mean lifespan did not change, and the longest-lived 10% lived 13.3% longer (Anisimov 2003). The human work is a 20-day sublingual study in which a urinary melatonin metabolite rose 1.7-fold in about 20 women with low melatonin output while placebo did not; blinding was not described and sleep was not measured (Ivko 2020) (FDA epitalon review 2026). Almost all of it comes from the developer's institute in St. Petersburg.

Put plainly: sermorelin has shown it moves the hormone it is supposed to move, in people, at adequate doses. Epitalon has not shown it moves anything in people beyond a urine marker. Neither has shown that what it moves changes how you age.

One caveat applies to sermorelin specifically: the doses clinics prescribe are often well below those in the trials, which our sermorelin dosage chart sets out. A sermorelin prescription is only as evidence-based as its dose and the IGF-1 test that follows it.

Different safety records

Sermorelin went through an FDA approval program. In children, transient facial flushing and pain at the injection site were the most commonly reported adverse events (Prakash & Goa 1999), and the 6-week trial in older men reported no significant adverse effects (Vittone 1997). The longer-term questions are the ones that come with raising growth hormone and IGF-1 (fluid retention, joint pain, insulin resistance, caution with any active cancer), covered in the sermorelin profile.

Epitalon has no comparable record. FDA found no clinical study that assessed its safety, no human pharmacokinetic data, and no acute, repeat-dose, reproductive or two-year cancer studies in animals. Its reviewers also raised a specific concern: a drug sold to activate telomerase and lengthen telomeres could, with continuous use, help cells evade the limits that keep them from becoming cancerous, and the mouse studies were too short and narrow to rule that out (FDA epitalon review 2026). That is a theoretical risk, not an observed one, but nobody has done the work to dismiss it.

Legal status and cost

Sermorelin can be compounded by a state-licensed 503A pharmacy on a valid prescription because it was the active ingredient of an FDA-approved drug, and it is not on FDA's Category 2 list. Through telehealth it costs about $150 to $400 a month in October 2026, usually including the clinician, according to our cost guide.

Epitalon cannot be compounded. It came off Category 2 on April 15, 2026, and on July 24, 2026 FDA's advisory committee, reviewing it for insomnia, voted 7 to 4 with 1 abstention to recommend it for the permitted list, against the advice of FDA's reviewers (HPM 2026) (FDA epitalon review 2026). FDA has not issued a rule, so no pharmacy may make it, and vials sold online are unapproved drugs; our legal tracker follows the rulemaking.

The same tracker settles a question people often ask alongside this one. Tesamorelin, another GHRH analog, is FDA-approved for HIV-associated abdominal fat, but as a biological product it is available only as the brand Egrifta and cannot be compounded.

Which one, if any

• You have symptoms and a documented low IGF-1: sermorelin is the defensible option, prescribed by a clinician who measures IGF-1 before and after and stops it if nothing moves. If you are prescribed it, the reconstitution calculator works from the concentration on your pharmacy label.
• You want better sleep: neither. No sermorelin trial has measured sleep objectively, and epitalon has never been tested on it. Start with an evaluation; the sleep guide explains what works.
• You want longer telomeres or a longer life: neither has shown it in people. The longevity ranking puts the peptides with outcome data first.
• You were offered both as a 'longevity stack': no study has combined them, and the epitalon half cannot come from a licensed pharmacy.

Bottom line

Sermorelin and epitalon share a shelf, not an evidence base. Sermorelin is a hormone fragment with an approval history, small human trials showing it raises growth hormone and IGF-1, a known side-effect profile and a legal prescription path; its limits are modest effects and clinic doses below the studied ones. Epitalon is a telomere hypothesis supported in cells and mice, with a urine marker as its best human result, no safety data and no legal source. If one of them is worth paying for, it is sermorelin, for a documented reason, with labs. Epitalon is worth watching, not buying.

Frequently asked questions

+−What are the differences between epitalon and sermorelin?

Sermorelin is the first 29 amino acids of growth hormone-releasing hormone; it makes the pituitary release its own growth hormone, was FDA-approved for children with growth hormone deficiency, has small human trials in older adults and can be compounded on prescription. Epitalon is a synthetic four-amino-acid peptide modeled on a calf pineal extract, sold for telomeres and longevity on the strength of cell, mouse and small human reports, and no US pharmacy may compound it. One is a prescribable hormone secretagogue with modest effects; the other is a research chemical with a longevity story.

+−Is epitalon or sermorelin better for sleep?

Neither has been shown to improve sleep. No sermorelin trial has measured sleep objectively, and a related GHRH analog left sleep quality unchanged in older adults over 16 weeks. Epitalon has never been tested on sleep at all; it raised a urinary melatonin marker in about 20 women. FDA reviewed epitalon for insomnia in 2026 and found no evidence it works. Chronic insomnia has treatments with real evidence, starting with cognitive behavioral therapy.

+−Is epitalon or sermorelin better for anti-aging?

Neither has been shown to slow human aging. Sermorelin raises growth hormone and, at adequate doses, IGF-1 in older adults, with small and inconsistent effects on strength and body composition. Epitalon's longevity case rests on telomerase activation in cells and on mice whose average lifespan did not change. For a documented low IGF-1 with symptoms, sermorelin is the one a clinician can prescribe and monitor.

+−Can you take epitalon and sermorelin together?

No study has combined them, so any benefit or interaction is unknown. The practical problem comes first: epitalon cannot be legally compounded in October 2026, so a 'stack' of the two pairs a pharmacy-made sermorelin with a research vial of unverified content. A clinic that offers both in one plan is supplying epitalon outside the law.

+−Why can a pharmacy make sermorelin but not epitalon?

A 503A pharmacy may compound a bulk ingredient only if it has a USP monograph, is a component of an FDA-approved drug, or is on FDA's permitted list. Sermorelin passes because it was the active ingredient of the approved drug Geref. Epitalon passes none of the three: it was never approved, has no monograph, and although FDA's advisory committee recommended it in July 2026, FDA has not added it to the list.

+−Which is safer, epitalon or sermorelin?

Sermorelin has a known safety profile from its approval program and trials: injection-site reactions and flushing are the common problems, and raising growth hormone carries theoretical risks such as fluid retention and higher blood sugar. Epitalon has no human safety studies, no pharmacokinetic data and no long-term animal toxicity studies, and FDA's reviewers flagged a theoretical cancer risk from activating telomerase. Known modest risks beat unknown ones.

Sources

1. StudyCorpas E et al. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab 1992;75:530-5. (1992)
2. StudyVittone J et al. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism 1997;46:89-96. (1997)
3. StudyKhorram O, Laughlin GA, Yen SS. Endocrine and metabolic effects of long-term administration of [Nle27]GHRH-(1-29)-NH2 in age-advanced men and women. J Clin Endocrinol Metab 1997;82:1472-9. (1997)
4. ReviewPrakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs 1999;12:139-57. (1999)
5. StudyAnisimov VN et al. Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice. Biogerontology 2003;4:193-202. (2003)
6. StudyIvko OM et al. AEDG peptide regulates human circadian rhythms genes expression during pineal gland accelerated aging. Adv Gerontol 2020;33:429-35 (in Russian; English edition 2021). (2020)
7. RegulatoryFDA. Evaluation of epitalon-related bulk drug substances (epitalon free base and epitalon acetate) for the 503A bulks list, evaluated for insomnia (memo dated May 12, 2026), briefing document for the Pharmacy Compounding Advisory Committee meeting of July 23-24, 2026. Read October 10, 2026. (2026)
8. NewsSnow CD, Palmer KL, Bass M. PCAC adds two more bulk drug substances for the 503A list (epitalon, semax; emideltide rejected). FDA Law Blog, July 28, 2026. (2026)